Old Web
English
Sign In
Acemap
>
authorDetail
>
Michael Serbin
Michael Serbin
Neurocrine Biosciences
Medicine
Deutetrabenazine
Valbenazine
Tardive dyskinesia
Clinical trial
5
Papers
8
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
In Reply to Xue W, Ribalov R, Zhou Z-Y et al. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103-113
2021
Journal of Medical Economics
Michael Serbin
Charles Yonan
Michael L. Ganz
Show All
Source
Cite
Save
Citations (0)
Cost-effectiveness of opicapone and entacapone in reducing off-time in Parkinson's Disease patients treated with levodopa/carbidopa.
2021
Journal of Medical Economics
Ryan N. Hansen
Kangho Suh
Michael Serbin
Chuck Yonan
Sean D. Sullivan
Show All
Source
Cite
Save
Citations (1)
Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia.
2021
Journal of Medical Economics
Michael L. Ganz
Ameya Chavan
Rahul Dhanda
Michael Serbin
Charles Yonan
Show All
Source
Cite
Save
Citations (2)
Efficacy of Opicapone Compared to Entacapone in Parkinson’s Patients with Motor Fluctuations and ON Hoehn & Yahr ≤ 2.5: A Post Hoc Analysis of BIPARK-1 (4429)
2020
Neurology
Mark F. Lew
Robert A. Hauser
S. Isaacson
Joaquim J. Ferreira
Michael Serbin
Khodayar Farahmand
Kurt Olson
Olga Klepitskaya
F. Rocha
Patrício Soares-da-Silva
Grace S. Liang
Show All
Source
Cite
Save
Citations (0)
Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia.
2019
Journal of Comparative Effectiveness Research
Saurabh Aggarwal
Michael Serbin
Chuck Yonan
Show All
Source
Cite
Save
Citations (5)
1